0001181431-15-008322.txt : 20150615
0001181431-15-008322.hdr.sgml : 20150615
20150615170029
ACCESSION NUMBER: 0001181431-15-008322
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150612
FILED AS OF DATE: 20150615
DATE AS OF CHANGE: 20150615
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Avalanche Biotechnologies, Inc.
CENTRAL INDEX KEY: 0001501756
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 205258327
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1035 O?BRIEN DRIVE, SUITE A
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650-272-6269
MAIL ADDRESS:
STREET 1: 1035 O?BRIEN DRIVE, SUITE A
CITY: MENLO PARK
STATE: CA
ZIP: 94025
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bain Linda
CENTRAL INDEX KEY: 0001578407
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36579
FILM NUMBER: 15931787
MAIL ADDRESS:
STREET 1: C/O BLUEBIRD BIO, INC.
STREET 2: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
rrd425765.xml
X0306
4
2015-06-12
0
0001501756
Avalanche Biotechnologies, Inc.
[AAVL]
0001578407
Bain Linda
C/O AVALANCHE BIOTECHNOLOGIES, INC.
1035 O'BRIEN DRIVE, SUITE A
MENLO PARK
CA
94025
0
1
0
0
Chief Financial Officer
Common Stock
2015-06-12
4
M
0
3500
3.15
A
12500
D
Common Stock
2015-06-12
4
S
0
3500
39.9414
D
9000
D
Stock Option (Right to Buy)
3.15
2015-06-12
4
M
0
3500
0.00
D
2024-04-21
Common Stock
3500
233000
D
Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
This transaction was executed in multiple trades in prices ranging from $39.8100 to $40.1900, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Twenty-five percent (25%) of the shares subject to the option vested and became exercisable on the first anniversary measured from April 14, 2014, and the remaining shares subject to the option vest in 36 successive, equal installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
/s/ Michael Swartzburg, Attorney-in-Fact for Linda Bain
2015-06-15